Shionogi & Co., Ltd.
4507・Prime Market・Pharmaceuticals
Governance
Transitioned to a company with an audit and supervisory committee in June 2025. The Board of Directors consists of 11 members (including 7 outside directors, all of whom are independent officers), with outside directors holding a majority, and a diverse composition including 3 women and 1 non-Japanese national. A voluntary Nomination Advisory Committee and Compensation Advisory Committee have been established, both of which are composed of a majority of outside officers.
Risk Management
The company has established an Enterprise Risk Management framework based on the 'SHIONOGI Group Risk Management Policy,' under which each organization proactively manages risk as a risk owner. The company-wide risk management function presents and reports the annual plan to the Management Committee and the Board of Directors, and a comprehensive framework has been built that also includes crisis management for pandemics, natural disasters, cyberattacks, and other events.
Shareholder Returns
Aiming for stable dividend increases using DOE of 4% as the dividend indicator. Annual dividend for FY2026 (ending March 2026) is ¥71 per share (interim ¥33 + year-end ¥38), with a payout ratio of 29.4%. FY2027 (ending March 2027) forecast is ¥76 (interim ¥38 + year-end ¥38). Share buybacks can be flexibly implemented via board resolution as stipulated in the Articles of Incorporation.
Dividend Policy
The company aims to steadily raise dividends in line with growth in corporate value, using a DOE of 4% or more as the dividend indicator. The annual dividend for FY2026 (ending March 2026) is ¥71 per share (interim ¥33 + year-end ¥38), with a payout ratio of 29.4% and a dividend-to-equity attributable to owners of the parent ratio of 4.0%. The forecast for FY2027 (ending March 2027) is an annual dividend of ¥76 (interim ¥38 + year-end ¥38), with a forecast payout ratio of 30.8%. Interim dividends are determined by board resolution, and year-end dividends by resolution of the shareholders' meeting.
ESG
As part of its climate change response, the company endorses the TCFD recommendations and has set targets to reduce Scope 1 and 2 emissions by 46.2% (versus FY2019 (ending March 2019)) and to achieve a renewable energy electricity adoption rate of 90% or more by FY2030 (ending March 2030). In FY2025 (ending March 2025), the company achieved a 26.8% reduction in its own emissions versus FY2019 (ending March 2019). In terms of human capital, the company has set and manages diversity and health management indicators such as a ratio of women in management positions of 16.4% (target of 18% or more by FY2027 (ending March 2027)) and a male childcare leave take-up rate of 75.8%.
Last updated: June 19, 2026